Showing results (291-300 of 6,006) with videos related to

Sort By:
Pageof 601
Molecular Cancer Therapeutics|October 14, 2003
Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cellsYajaira Suárez, Laura González, Ana Cuadrado, et al.
Molecular Cancer Therapeutics|October 14, 2003
MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivoDeepak Sampath, Carolyn M Discafani, Frank Loganzo, et al.
Molecular Cancer Therapeutics|October 14, 2003
Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenograftsRachel L Cowen, Adam V Patterson, Brian A Telfer, et al.
Molecular Cancer Therapeutics|May 10, 2013
NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinomaRoshan J Thapa, Peirong Chen, Mitchell Cheung, et al.
Molecular Cancer Therapeutics|May 10, 2013
Drug repurposing for gastrointestinal stromal tumorZiyan Y Pessetto, Scott J Weir, Geetika Sethi, et al.
Molecular Cancer Therapeutics|April 12, 2013
SMARCB1/INI1 genetic inactivation is responsible for tumorigenic properties of epithelioid sarcoma cell line VAESBJMonica Brenca, Sabrina Rossi, Erica Lorenzetto, et al.
Molecular Cancer Therapeutics|March 16, 2013
A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivoHidetoshi Kuruma, Hiroaki Matsumoto, Masaki Shiota, et al.
Molecular Cancer Therapeutics|February 16, 2013
Transient exposure to quizartinib mediates sustained inhibition of FLT3 signaling while specifically inducing apoptosis in FLT3-activated leukemia cellsRuwanthi N Gunawardane, Ronald R Nepomuceno, Allison M Rooks, et al.
Molecular Cancer Therapeutics|February 22, 2013
Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancersSerengulam V Govindan, Thomas M Cardillo, Robert M Sharkey, et al.
Molecular Cancer Therapeutics|May 21, 2013
Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancerTian Ma, Fabrizio Galimberti, Cherie P Erkmen, et al.
Pageof 601